Pathways and targets in hepatocellular carcinoma

Area of Science:

• Hepatology
• Oncology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) incidence is increasing in Western countries.
• Traditional cytotoxic chemotherapy has shown limited efficacy in improving HCC outcomes.
• The need for effective systemic therapies in HCC management is critical.

Purpose of the Study:

• To review the current 'state of the art' in hepatocellular carcinoma (HCC) management.
• To focus on the role and advancements of targeted systemic therapies for HCC.
• To summarize molecular targets and pathways relevant to HCC treatment.

Main Methods:

• Comprehensive literature search of PubMed and MEDLINE databases.
• Inclusion of articles published up to June 1, 2012.
• Synthesis of information on targeted agents and clinical trials in HCC.

Main Results:

• Sorafenib demonstrates a survival gain in HCC patients, but responses are often transient.
• Sorafenib is associated with significant dermatologic and gastrointestinal side effects.
• Numerous targeted agents inhibiting angiogenesis, Ras/Raf/MAPK, and other pathways are under investigation.

Conclusions:

• Targeted systemic therapies represent a significant advancement in HCC management.
• Further research is needed to optimize efficacy and manage toxicity of targeted agents.
• Ongoing clinical trials are exploring novel molecular targets for HCC treatment.